首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1510388

视网膜疾病治疗市场规模、份额和成长分析：按类型、剂型、分销管道和地区划分 - 产业预测，2024-2031 年

Retinal Disorder Treatment Market Size, Share, Growth Analysis, By Type(Macular Degeneration, Diabetic Retinopathy, Others), By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年07月05日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年视网膜疾病治疗市场规模估值为25亿美元，预测期间（2024-2031年）复合年增长率为8.50%，从2023年的27.1亿美元增至2031年的52.1亿美元，预计还会增长。

视网膜疾病治疗市场是医疗保健领域一个充满活力且快速发展的领域，专注于影响视力的各种视网膜疾病的诊断和管理。影响市场的主要趋势包括由于人口老化和糖尿病盛行率增加而导致老年黄斑部病变（AMD）、糖尿病视网膜病变和视网膜静脉阻塞的盛行率老龄化。如果不及时治疗，这些疾病可能会导致视力障碍和失明，从而增加对有效治疗的需求。重要的进展包括抗 VEGF 药物、基因疗法和干细胞疗法等新疗法。 Lucentis和 Eilea 等抗 VEGF 药物彻底改变了湿性AMD和糖尿病视网膜病变的治疗方法，改善了玻璃体内注射的治疗效果。基因疗法有望改善某些遗传性视网膜疾病的长期或永久性视力。光同调断层扫瞄(OCT) 和眼底摄影等视网膜成像技术的进步增强了诊断和监测，从而可以进行早期疗育和个人化治疗。儘管技术取得了这些进步，但挑战包括治疗成本上升、持续监测的需要以及监管和报销问题。总而言之，在人口老化和视网膜疾病盛行率上升的背景下，视网膜疾病治疗市场的特征是技术创新和成长机会。希望持续的研究和开发能够带来进一步的进步并改善视网膜疾病患者的生活品质。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 海湾合作委员会国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Novartis（Switzerland）
Roche（Switzerland）
Regeneron Pharmaceuticals（USA）
Genentech（USA）
Allergan（Ireland）
Bausch Health Companies（Canada）
Alimera Sciences（USA）
Ophthotech Corporation（USA）
Spark Therapeutics（USA）
Kodiak Sciences（USA）
Santen Pharmaceutical（Japan）
Bayer AG（Germany）
Regenxbio（USA）
Chengdu Kanghong Pharmaceutical Group（China）
Graybug Vision（USA）
Apellis Pharmaceuticals（USA）
Adverum Biotechnologies（USA）
Clearside Biomedical（USA）
Acucela Inc.（USA）
PanOptica, Inc.（USA）
Opthea Limited（Australia）
Oxurion NV（Belgium）
Kala Pharmaceuticals（USA）
Hemera Biosciences（USA）
Tyrogenex（USA）

简介目录

Product Code: SQMIG35I2302

Retinal Disorder Treatment Market size was valued at USD 2.50 Billion in 2022 and is poised to grow from USD 2.71 Billion in 2023 to USD 5.21 Billion by 2031, at a CAGR of 8.50% during the forecast period (2024-2031).

The retinal disorder treatment market is a dynamic and rapidly evolving sector within healthcare, focused on diagnosing and managing various vision-affecting retinal conditions. Key trends influencing the market include the rising prevalence of age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion due to aging populations and increasing diabetes rates. These conditions can lead to vision impairment or blindness if untreated, driving demand for effective treatments. Significant developments include novel therapies like anti-VEGF drugs, gene therapies, and stem cell therapies. Anti-VEGF drugs, such as Lucentis and Eylea, have revolutionized treatments for wet AMD and diabetic retinopathy, offering improved outcomes through intravitreal injections. Gene therapies promise long-lasting or permanent vision improvement for certain inherited retinal disorders. Advancements in retinal imaging technologies, like optical coherence tomography (OCT) and fundus photography, have enhanced diagnosis and monitoring, enabling earlier intervention and personalized treatments. Despite these innovations, challenges include high treatment costs, the need for ongoing monitoring, and regulatory and reimbursement issues. In conclusion, the retinal disorder treatment market is characterized by innovation and growth opportunities, driven by an aging population and increasing retinal condition prevalence. Continued research and development are likely to bring further advancements, improving the quality of life for those affected by retinal disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Disorder Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Disorder Treatment Market Segmental Analysis

The global retinal disorder treatment market is segmented on the basis of type, dosage form, distribution channel and region. By type, the market is segmented into Macular Degeneration (Dry Macular Degeneration, Wet Macular Degeneration), Diabetic Retinopathy, and Others. By dosage form, the market is segmented into gels, eye solutions, capsules & tablets, eye drops, and ointments. By distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Retinal Disorder Treatment Market

The aging population significantly drives the retinal disorder treatment market, as older individuals are more prone to conditions like age-related macular degeneration (AMD) and diabetic retinopathy. With the elderly population on the rise, the prevalence of these disorders is expected to increase, thereby boosting demand for treatments and therapies. Additionally, technological advancements in ophthalmic treatments, such as anti-VEGF therapies and advanced retinal imaging techniques, have enhanced the diagnosis and management of retinal disorders, offering more effective and less invasive treatment options, leading to better patient outcomes.

Restraints in the Retinal Disorder Treatment Market

High treatment costs for retinal disorders, including expensive anti-VEGF therapies and surgical procedures, significantly restrain the market. These costs can limit access to treatment, especially in regions with limited healthcare resources or inadequate insurance coverage. Additionally, the effective treatment of retinal disorders requires specialized ophthalmologists and retinal surgeons. However, a shortage of these skilled professionals in certain areas further impedes timely access to necessary treatments for patients.

Market Trends of the Retinal Disorder Treatment Market

Significant advancements in retinal imaging and diagnostic technologies, including optical coherence tomography (OCT) and adaptive optics, have greatly improved the early detection and diagnosis of retinal disorders, allowing for timely treatment to prevent further vision loss. The integration of AI and machine learning algorithms into retinal imaging has further enhanced diagnostic accuracy and efficiency, benefiting healthcare providers. Concurrently, the treatment landscape for retinal disorders is evolving with biologic and gene therapy approaches. These innovative treatments target the genetic causes of conditions like retinitis pigmentosa and Leber congenital amaurosis. Gene therapy, particularly, has shown promising clinical trial results and received regulatory approvals for specific conditions, offering long-term benefits by addressing genetic defects and providing hope for patients with previously untreatable disorders.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Regulatory Landscape
Patent Analysis
Pestel Analysis
Key Success Factors
Market Attractiveness Index
Degree of Competition
Top Investment Pockets
Ecosystem Mapping

Retinal Disorder Treatment Market by Type

Market Overview
Macular Degeneration
- Dry Macular Degeneration
- Wet Macular Degeneration
Diabetic Retinopathy
Others

Retinal Disorder Treatment Market by Dosage Form

Market Overview
Gels
Eye Solutions
Capsules & Tablets
Eye Drops
Ointments

Retinal Disorder Treatment Market by Distribution Channel

Market Overview
Hospital
Online
Retail

Retinal Disorder Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Novartis (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genentech (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bausch Health Companies (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alimera Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ophthotech Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Spark Therapeutics (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Santen Pharmaceutical (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regenxbio (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chengdu Kanghong Pharmaceutical Group (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Graybug Vision (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Apellis Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adverum Biotechnologies (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Clearside Biomedical (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acucela Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PanOptica, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Opthea Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oxurion NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kala Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hemera Biosciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Tyrogenex (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments